Stock Events

Stock Events

Aptamer Group 

€0
0
-€0-83.33% Wednesday 07:46

Statistics

Day High
0
Day Low
0
52W High
0.01
52W Low
0
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

22OctExpected
Q3 2024
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow P0J.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap39.51B
Alnylam Pharmaceuticals focuses on RNAi therapeutics, closely related to aptamer technology used by Aptamer Group.
Ionis Pharmaceuticals
IONS
Mkt Cap12.44B
Ionis Pharmaceuticals specializes in antisense technology, which is similar to aptamer-based methods in targeting genetic disorders.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.48B
Arrowhead Pharmaceuticals is involved in developing RNAi therapeutics, a field closely related to aptamers.
Sarepta Therapeutics
SRPT
Mkt Cap2.27B
Sarepta Therapeutics engages in the development of RNA-based therapeutics, competing in the same broader biotech space as Aptamer.
CRISPR Therapeutics
CRSP
Mkt Cap4.98B
CRISPR Therapeutics is known for gene editing, a cutting-edge technology that competes with aptamer technology in genetic medicine.
Editas Medicine
EDIT
Mkt Cap283.93M
Editas Medicine specializes in CRISPR gene editing, competing in the genomic medicine field alongside aptamer technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.58B
Intellia Therapeutics is another key player in CRISPR technology, directly competing with companies developing alternative genetic therapies like aptamers.

About

Aptamer Group PLC, together with its subsidiaries, provides synthetic binders for research, diagnostics, and therapeutics in the United Kingdom, rest of Europe, the United States, and internationally. The company offers Optimer, a platform that enables the discovery and development of optimized DNA and RNA aptamers, which can bind to target molecules. Its platform is used in research reagent and analytical, bioprocessing, diagnostic, cosmetic and consumer health, and therapeutic applications. The company serves pharmaceutical, diagnostic, and bioprocessing companies. It has collaborations with Unilever, Neuro-Bio, the University of Glasgow, AstraZeneca, and Invizius. Aptamer Group PLC was founded in 2008 and is headquartered in York, the United Kingdom.
Show more...
CEO
Dr. Arron Craig Tolley
Employees
30
Country
United Kingdom
ISIN
GB00BNRRP542

Listings

STU
DE
P0J.STU
LSE
GB
APTA.LSE
F
DE
P0J.F

0 Comments

Share your thoughts

FAQ

What is Aptamer Group stock price today?▼
The current price of P0J.STU is €0 EUR — it has decreased by -83.33% in the past 24 hours. Watch Aptamer Group stock price performance more closely on the chart.
What is Aptamer Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Aptamer Group stocks are traded under the ticker P0J.STU.
Is Aptamer Group stock price growing?▼
P0J.STU stock has fallen by -83.33% compared to the previous week, the month change is a -0% fall, over the last year Aptamer Group has showed a -83.33% decrease.
When is the next Aptamer Group earnings date?▼
Aptamer Group is going to release the next earnings report on October 20, 2026.
How many employees does Aptamer Group have?▼
As of May 05, 2026, the company has 30 employees.
In which sector is Aptamer Group located?▼
Aptamer Group operates in the Health & Wellness sector.
When did Aptamer Group complete a stock split?▼
Aptamer Group has not had any recent stock splits.
Where is Aptamer Group headquartered?▼
Aptamer Group is headquartered in York, United Kingdom.